Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. - Wikidata - awgldk - TriplyDB

Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies.

Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies.

http://www.wikidata.org/entity/Q33739583

about

Treatment of colorectal cancer in the elderly Anti-angiogenic agents in metastatic colorectal cancer Targeted anti-vascular therapies for ovarian cancer: current evidence Angiogenic inhibitors for older patients with advanced colorectal cancer: does the age hold the stage?The place of targeted agents in the treatment of elderly patients with metastatic colorectal cancer Decision-making in geriatric oncology: systemic treatment considerations for older adults with colon cancer.Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen.The effect of geriatric intervention in frail elderly patients receiving chemotherapy for colorectal cancer: a randomized trial (GERICO).First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study.Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials Bevacizumab treatment in the elderly patient with metastatic colorectal cancer.Systems pharmacology assessment of the 5-fluorouracil pathway.Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry Chemotherapy for colorectal cancer in the elderly.Bevacizumab in clinical practice: prescribing appropriateness relative to national indications and safety.Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer.Palliative chemotherapy for patients 70 years of age and older with metastatic colorectal cancer: a single-centre experience Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer.Senior adult oncology.Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience.Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study.Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequences.Challenges in the management of older patients with colon cancer Assessment of solid cancer treatment feasibility in older patients: a prospective cohort study.Treatment of older patients with colorectal cancer: a perspective review.Role of the antiangiogenic agent bevacizumab in the treatment of elderly patients with metastatic colorectal cancer.Targeted agents: review of toxicity in the elderly metastatic colorectal cancer patients.Targeting the vasculature of visceral tumors: novel insights and treatment perspectives.Treatment of colorectal cancer in older patients.Palliative treatment of metastatic colorectal cancer: what is the optimal approach?Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013.Bevacizumab: a review of its use in advanced cancer.Impact of VEGF gene polymorphisms in elderly cancer patients: clinical outcome and toxicity.Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence.Pulmonary metastasectomy in elderly colorectal cancer patients: a retrospective single center study.Gossypol sensitizes the antitumor activity of 5-FU through down-regulation of thymidylate synthase in human colon carcinoma cells.Bevacizumab safety in Japanese patients with colorectal cancer.Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy.

P2860

Q26781457-BE1A4FCA-3DE2-49ED-B74B-EAF9318BEDFC Q26801911-68E1718C-C693-4378-A2E1-51C07A68C2A1 Q26830287-1112C996-290F-4CC5-806D-4E83516F7059 Q27002538-17489A62-D943-4694-966A-24EA7E0BF50B Q27011366-43B87565-6FF2-4709-B756-AF2788EC136B Q30244769-77BC0A44-DDB6-4AB5-AA80-6E75F9D573BF Q33563281-B1270FB6-4B31-423D-9CBA-DAC50C6B3A61 Q33778129-4E523447-69E4-4475-AD5C-6D0B2B574E47 Q33851067-5B519B3E-2D79-4B5D-BA54-DEC3DD4D4B44 Q33918152-5A80B159-CA01-430D-8CB2-F86448BB2E61 Q34347083-CF2E354B-16A2-475A-9D74-21A29C926D23 Q34654605-48415B05-3444-4F24-8260-42F2F115806D Q34899949-9F8CA5AF-F26C-4534-81E5-02BADB4AE12A Q35072321-C92A7C50-DE2C-4305-AF4B-C5ECF1F864FB Q35130633-CEA65A67-3B04-429A-AF99-3B130F465C81 Q35567604-A4A342EE-9B8F-41AE-A863-185DAFA3C271 Q35705156-B81F4F9D-FB1B-4AD1-871F-89FC74EC48F8 Q35913223-DD19C16A-B615-4ADC-A01B-020A621AA564 Q36169867-B50AA5E3-4CAD-4CC2-BCDA-C13B3B5A65AB Q36286831-7CD4132C-F6FB-4D94-AC65-C4B64E7C28E0 Q36851424-90A0C4AA-3E9B-4C5C-B5B8-8F9BE3D9B498 Q36857679-BFF49EB9-A5BE-4217-8AF9-6BA3827305C6 Q36862836-2ED3E636-ECBA-487A-A193-9D7DFD6B0128 Q36909199-D837C7D9-85FD-4A95-9C51-12E98485382B Q37598467-7BE58089-4DDA-4FA4-BE8B-AEAECD87932E Q37644543-5007CC59-8561-4060-A5A3-E6D0A280961D Q37704350-EEE8A8F6-82FE-49C4-84F5-492C9C30D6E7 Q37820653-0BC0DF99-617D-4AF1-B32D-B830C3DC5589 Q37954162-2C0550DF-366B-4D81-AB1D-54291BEEF505 Q37993393-D6FD6835-05C0-45BE-9C45-155D30B90A1B Q38050375-69B6EDB4-4EBC-4DB2-B277-E3CB188F39D0 Q38167675-9FE93B95-6310-4EC6-921C-C9FFE61FDA0F Q38228522-CE41504D-87DB-43E3-BEA7-9ABF91792662 Q38260176-A86424E7-CFA0-4D66-B884-A8EE424A395A Q38307997-905701F8-1DC9-4475-A052-726D7538EBEA Q38961110-910C04B3-2B52-4008-889E-1BB73415CFF2 Q40563745-6404BEDA-CFD9-4A4B-9585-95034DC48284 Q40699159-C58E1CF6-C205-4793-8B50-F90F0ADFFBC6 Q40972698-87BE83DA-30F7-4818-B8FB-9C1A67D933F2 Q41044367-FAED3898-B9E4-432B-BBB8-0318E4B6222E

P2860

Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies.

http://www.wikidata.org/entity/Q33739583

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

name

Effect of bevacizumab in older ...... is of four randomized studies.

@ast

Effect of bevacizumab in older ...... is of four randomized studies.

@en

type

label

Effect of bevacizumab in older ...... is of four randomized studies.

@ast

Effect of bevacizumab in older ...... is of four randomized studies.

@en

prefLabel

Effect of bevacizumab in older ...... is of four randomized studies.

@ast

Effect of bevacizumab in older ...... is of four randomized studies.

@en

P1433

Q33739583-E62259EA-C0E5-4936-9224-B6969DA75F66

P1476

Q33739583-A3F2B46E-2CE6-4F7A-B88B-0E0681B4A0CA

P2093

Q33739583-4D123200-7F47-461D-AC14-A59067AA6C3F

Q33739583-5B03ACB3-93AD-4A48-98F7-8E5A711DA4E3

Q33739583-7178A5D3-71E4-4B77-973E-E020E8BFA928

Q33739583-71F5D062-8CBD-4594-81F3-01D41BA785C3

Q33739583-D6AEDAF2-34E7-4F4A-8E4E-6EDED8F14026

P2860

Q33739583-062AB668-FADC-458E-901C-6D222FB6339D

Q33739583-0E48208A-E662-436F-8352-D7FF48AC3B96

Q33739583-160F0A4D-630B-4425-99BC-F8E2C21C8BFD

Q33739583-21AA8D87-26CC-4441-AA2B-66FD221569CF

Q33739583-2A27B416-85BB-49E0-BCA3-7D10B67C9C81

Q33739583-3B27F612-9523-44CD-AAA2-F3BD09182748

Q33739583-80DB120B-6C51-4F47-8566-5DDC551CA746

Q33739583-8668F4F4-9E1B-4098-99DD-6316B0EBA302

Q33739583-99AE8651-AFFD-49D3-81D0-15AB4B8AD731

Q33739583-9F704176-B5AF-4493-8378-8B65010A9157

P2888

Q33739583-D6ABACA6-1C1A-42C3-B162-D43280BDBFEF

P304

Q33739583-FBD603C1-7323-4CD0-AE4A-AED654912E41

P31

Q33739583-ACE87E68-B860-4FEF-88F6-D3F2D60DEF6A

P356

Q33739583-D0CE73FC-03A7-4EE7-A7AF-8FBE2ABBACEA

P433

Q33739583-E0BD77CE-2AE5-417D-989A-DF52BB34FB28

P478

Q33739583-2EC5E0CE-C06E-4EBF-B0D9-562A04585033

P50

Q33739583-883BA028-222F-4634-8CDF-688C26D91F1D

P577

Q33739583-FCAF182E-1D1A-48BB-8C5C-B504242480A2

P5875

Q33739583-93AB341C-15AF-4BAC-B9B8-B41F891BFBD4

P698

Q33739583-5E81B798-5927-41D7-8A4C-3E34833BE85F

P921

Q33739583-895D4120-ECDA-4D08-BA62-F3D9D3B86AB6

Q33739583-A9595E70-72F3-49C6-A0B5-2242E5A6BB6E

P932

Q33739583-7E037EE0-1CCE-45FE-B65D-BD983950B86E

P356

S00432-009-0712-3

P1433

Journal of Cancer Research and Clinical Oncology

P1476

Effect of bevacizumab in older ...... sis of four randomized studies

@en

P2093

Bruce J Giantonio

http://www.w3.org/2001/XMLSchema#string

Fairooz F Kabbinavar

http://www.w3.org/2001/XMLSchema#string

Herbert I Hurwitz

http://www.w3.org/2001/XMLSchema#string

James Cassidy

http://www.w3.org/2001/XMLSchema#string

Ulrich-Peter Rohr

http://www.w3.org/2001/XMLSchema#string

P2860

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

Age-related changes in risk factor effects on the incidence of thromboembolic and hemorrhagic stroke.

Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.

Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.

Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study.

The impact of age on the incidence and prognosis of initial acute myocardial infarction: the Worcester Heart Attack Study.

P2888

s00432-009-0712-3

P304

737-743

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00432-009-0712-3

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

136

http://www.w3.org/2001/XMLSchema#string

P50

Leonard B. Saltz

P577

2009-11-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38081112

http://www.w3.org/2001/XMLSchema#string

P698

19904559

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

2841755

http://www.w3.org/2001/XMLSchema#string